Keliximab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458270545

| type = mab

| mab_type = mab

| source = xi/i

| target = CD4

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration = intravenous

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 174722-30-6

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 62L6LCF5EU

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Keliximab is a monoclonal antibody for the treatment of severe chronic asthma. It suppresses the immune reaction by binding to white blood cells via the protein CD4.{{cite journal | vauthors = Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC | title = Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma | journal = Lancet | volume = 352 | issue = 9134 | pages = 1109–13 | date = October 1998 | pmid = 9798587 | doi = 10.1016/S0140-6736(97)12261-9 | s2cid = 29868851 }} The drug is a chimeric antibody from Macaca irus and Homo sapiens.{{cite journal | title = Proposed INN List | url =https://www.who.int/medicinedocs/index/assoc/s14161e/s14161e.pdf | archive-url =https://web.archive.org/web/20081113133319/http://www.who.int/medicinedocs/index/assoc/s14161e/s14161e.pdf | url-status =dead | archive-date =November 13, 2008 | journal = WHO Drug Information | volume = 10 | issue = 4 | date = 1996 }}